Author Topic: Another MS drug class causes concern for COVID vaccine protection  (Read 60 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
Another MS drug class causes concern for COVID vaccine protection
« on: September 24, 2021, 02:57:50 pm »
From MedPage Today (September 24, 2021)--"Another MS Drug Class Causes Concern for COVID Vaccine Protection":


https://www.medpagetoday.com/neurology/multiplesclerosis/94711
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Article in JAMA Neurology (September 23)
« Reply #1 on: September 25, 2021, 09:28:49 pm »
This is the study referred to in the post above--in JAMA Neurology (September 23, 2021), "Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis":


https://bit.ly/3lZLBDZ
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
33 Views
Last post November 30, 2020, 03:46:43 pm
by agate
0 Replies
55 Views
Last post January 13, 2021, 02:32:50 pm
by agate
0 Replies
36 Views
Last post February 07, 2021, 09:37:14 pm
by agate
0 Replies
30 Views
Last post April 15, 2021, 08:22:39 pm
by agate
0 Replies
25 Views
Last post February 15, 2022, 03:10:12 pm
by agate